AstraZeneca (United Kingdom)

Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca

Biocatalysis is becoming a strategic manufacturing capability at AstraZeneca, enabling selective transformations under milder conditions and with the potential to reduce waste and resource intensity relative to conventional routes. This review summarizes how AstraZeneca is embedd...

Tozorakimab to Prevent COPD Exacerbations

BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations despite receiving standard-of-care inhaled maintenance therapy. Dysregulated interleukin-33 signaling is implicated in the pathogenesis of COPD. Tozorakimab is a monoclonal antibody tha...

Live Attenuated Influenza Vaccine (LAIV) for Children for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

Both inactivated influenza vaccine and live attenuated influenza vaccine (LAIV) (indicated for use in children aged 2–17 years) effectively prevent influenza transmission and related outcomes. Despite high transmission among children, vaccination practices in Sweden focus primari...

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics

Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...